Who is eligible for clinical trial NCT04233749?

Participants must meet the protocol's inclusion criteria for Lichen Planus Pigmentosus. The stated age range is 18 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT04233749 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2025-09-02

The Efficacy of Tranexamic Acid in the Treatment of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans (NCT04233749)

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Henry Ford Health System

🩺 Plain-English Summary (8th-Grade Level)

There are currently no effective treatments for lichen planus pigmentosus (LPP) and erythema dyschromicum perstans (EDP). Tranexamic acid, which may downregulate pigmentation through a reduction in plasmin, has been shown to decrease pigmentation in patients with melasma, another pigmentary disorder. Given that LPP, EDP, and melasma are all disorders of pigmentation with dermal involvement, it is possible that tranexamic acid can also reduce pigmentation in LPP and EDP as well.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (8 items).

Location: New Center One — Detroit, Michigan

Age range: 18 Years

🧪 Interventions in This Study

Tranexamic acid tablets (DRUG)

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Subject age 18 and older
Subject with a diagnosis of LPP, EDP, or AD
Subject able to understand requirements of the study and risks involved
Subject able to sign a consent form
Subject to have discontinued all topical or oral medications, with the exception of sunscreen, used to treat pigmentary abnormalities one month prior to treatment

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Personal history of clotting disorder or thromboembolic disease (deep vein thrombosis (DVT), stroke, etc)
Active malignancy, excluding non-melanoma skin cancer
Moderate to severe renal impairment
History of migraine with aura
Current anticoagulant therapy
Current use of hormonal contraception or hormone replacement therapy in the last 30 days
A woman who is lactating, pregnant, or planning to become pregnant

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

New Center One — Detroit, Michigan

📞 Contact the Study Coordinator

Phone: (313) 916-0426

Email: amiller5@hfhs.org

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All Lichen Planus Pigmentosus clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗